2008-08-12 11:19:02 -
Commercial and Pipeline Insight - Fibromyalgia - Approvals legitimize condition and expose underserved patient population - a new market research report on www.companiesandmarkets.com Introduction
With a considerable patient potential and large medical unmet need, the untapped fibromyalgia market represents a lucrative opportunity for pharmaceutical companies. Estimated to total around $650m in 2007 in the seven major markets, forecasts show the market to grow to over $2.4 billion in 2017.
Scope
*Analysis of clinical trial design and treatment guidelines in fibromyalgia.
*Fibromyalgia market sizing assessment with detailed methodology.
*Detailed
profiles of key late-stage pipeline products for fibromyalgia, with indication-specific forecasts to 2017.
*Case study analysis of Pfizer´s launch strategy for Lyrica (pregabalin) as well as assessment of development timeline.
Highlights
The approval of Pfizer´s Lyrica transformed the previously unchartered fibromyalgia market and provided a new level of validity for this disputed condition.
In June 2008, Eli Lilly´s dual serotonin and norepinephrine reuptake inhibitor (SNRI) Cymbalta (duloxetine) became the second FDA approved fibromyalgia treatment. Seven major market Cymbalta sales for fibromyalgia to peak at in excess of half a billion US dollars in 2012 prior to US and EU patent expiries.
As has been successful for Pfizer, televised direct-to-consumer (DTC) drug advertising campaigns will continue to be an important marketing tool for new players, providing a boost to sales and adding further legitimacy to the condition.
Reasons to Purchase
*Understand the current fibromyalgia market dynamics and how they are expected to evolve out to 2017.
*Benchmark key late-stage pipeline fibromyalgia compounds against the current market leading brand, supported by insight from key opinion leaders.
*Assess seven major market sales forecasts of marketed and key late-stage pipeline fibromyalgia drugs.
www.companiesandmarkets.com/Summary-Market-Report/Commercial-and ..
